Treatment
A multidisciplinary treatment-related adverse events management program resulted in improvement of related toxicities.
Pacritinib was found to be more effective than best available treatment at reducing spleen volume in myelofibrosis patients.
Adding navitoclax to ruxolitinib treatment in patients with persistent or progressive myelofibrosis led to durable splee
Myelofibrosis patients treated with fludarabine and busulfan along with TBI saw reduction in graft failure.
The Australian study put men with prostate cancer receiving androgen deprivation therapy on an exercise program.
Researchers evaluated whether outpatients suites could improve quality measures.
The basics of PTCy after hematopoietic cell transplantation for GVHD prevention, plus, how nurses can explain PTCy to patient
Cancer patients participating in medical tourism should know how seeking care outside of the US could disrupt care plan.
One concern that keeps patients from enrolling in clinical trials is the belief that their quality of life will suffer.
Extending the interval of port flushes to every 12 weeks did not increase the incidence of port-related adverse events.
Clinics also postponed or deferred radiation treatments and elective surgeries.
Kathi Mooney, PhD, RN, reported the results of a study looking at the combined intervention at the 2022 ASCO Annual Meeting.
An article appearing in the journal Therapeutic Advances in Infectious Disease called for research to explore the infectious ...
A recent article in the journal Biomedicines reviewed the potential of chimeric antigen receptor (CAR) T-cell therapy in ...
Post-transplant cyclophosphamide (PTCy) has shown promise in managing graft-versus-host-disease (GVHD) for patients ...
GATA2 deficiency was described in 2011, and shortly thereafter allogeneic hematopoietic stem cell transplantation was shown ...
Chimeric antigen receptor (CAR) T-cell therapy is a promising new option for treatment of hematologic malignancies, but many ...
Chimeric antigen receptor (CAR) T-cell therapy is a major advancement in the personalized treatment of hematological ...
Chimeric antigen receptor (CAR) T-cell therapy has provided a novel, effective treatment option for patients with relapsed or ...
Treatment with ivosidenib plus venetoclax, with or without azacitidine, had an acceptable safety profile and led to high ...
670 Madison Ave.
Manalapan, NJ 07726
© 2022 Mashup Media, LLC. All rights reserved.